GURUFOCUS.COM » STOCK LIST » USA » NYSE » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Piotroski F-Score
Switch to:

Myovant Sciences Piotroski F-Score

: 2 (As of Today)
View and export this data going back to 2016. Start your Free Trial

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Myovant Sciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Myovant Sciences's Piotroski F-Score or its related term are showing as below:

MYOV' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 2   Max: 5
Current: 2

During the past 7 years, the highest Piotroski F-Score of Myovant Sciences was 5. The lowest was 1. And the median was 2.


Myovant Sciences Piotroski F-Score Historical Data

The historical data trend for Myovant Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Piotroski F-Score
Premium Member Only Premium Member Only N/A 1.00 2.00 5.00 2.00

Myovant Sciences Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 2.00 2.00 2.00

Competitive Comparison

For the Biotechnology subindustry, Myovant Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Myovant Sciences Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun22) TTM:Last Year (Jun21) TTM:
Net Income was -21.591 + -63.445 + -59.285 + -21.239 = $-165.6 Mil.
Cash Flow from Operations was 36.599 + -91.894 + -100.087 + -76.005 = $-231.4 Mil.
Revenue was 77.902 + 54.44 + 57.567 + 116.492 = $306.4 Mil.
Gross Profit was 66.715 + 38.111 + 39.825 + 93.561 = $238.2 Mil.
Average Total Assets from the begining of this year (Jun21)
to the end of this year (Jun22) was
(727.77 + 679.54 + 604.292 + 520.011 + 460.13) / 5 = $598.3486 Mil.
Total Assets at the begining of this year (Jun21) was $727.8 Mil.
Long-Term Debt & Capital Lease Obligation was $365.1 Mil.
Total Current Assets was $426.8 Mil.
Total Current Liabilities was $226.2 Mil.
Net Income was -67.062 + -73.849 + -81.363 + -61.66 = $-283.9 Mil.

Revenue was 0 + 1.379 + 24.605 + 41.063 = $67.0 Mil.
Gross Profit was 0 + 1.379 + 22.64 + 34.77 = $58.8 Mil.
Average Total Assets from the begining of last year (Jun20)
to the end of last year (Jun21) was
(126.682 + 135.773 + 774.214 + 725.027 + 727.77) / 5 = $497.8932 Mil.
Total Assets at the begining of last year (Jun20) was $126.7 Mil.
Long-Term Debt & Capital Lease Obligation was $367.4 Mil.
Total Current Assets was $702.1 Mil.
Total Current Liabilities was $307.6 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Myovant Sciences's current Net Income (TTM) was -165.6. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Myovant Sciences's current Cash Flow from Operations (TTM) was -231.4. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun21)
=-165.56/727.77
=-0.22748945

ROA (Last Year)=Net Income/Total Assets (Jun20)
=-283.934/126.682
=-2.24131289

Myovant Sciences's return on assets of this year was -0.22748945. Myovant Sciences's return on assets of last year was -2.24131289. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Myovant Sciences's current Net Income (TTM) was -165.6. Myovant Sciences's current Cash Flow from Operations (TTM) was -231.4. ==> -231.4 <= -165.6 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun21 to Jun22
=365.131/598.3486
=0.61023123

Gearing (Last Year: Jun21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun20 to Jun21
=367.385/497.8932
=0.73787913

Myovant Sciences's gearing of this year was 0.61023123. Myovant Sciences's gearing of last year was 0.73787913. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun22)=Total Current Assets/Total Current Liabilities
=426.829/226.241
=1.88661206

Current Ratio (Last Year: Jun21)=Total Current Assets/Total Current Liabilities
=702.135/307.57
=2.28284618

Myovant Sciences's current ratio of this year was 1.88661206. Myovant Sciences's current ratio of last year was 2.28284618. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Myovant Sciences's number of shares in issue this year was 95.388. Myovant Sciences's number of shares in issue last year was 91.637. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=238.212/306.401
=0.77745177

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=58.789/67.047
=0.87683267

Myovant Sciences's gross margin of this year was 0.77745177. Myovant Sciences's gross margin of last year was 0.87683267. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun21)
=306.401/727.77
=0.42101351

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun20)
=67.047/126.682
=0.52925435

Myovant Sciences's asset turnover of this year was 0.42101351. Myovant Sciences's asset turnover of last year was 0.52925435. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Myovant Sciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Myovant Sciences  (NYSE:MYOV) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Myovant Sciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Myovant Sciences Business Description

Myovant Sciences logo
Traded in Other Exchanges
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
Valente Nancy director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Mehra Uneek officer: Principal Financial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Merendino Lauren officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Marek David C director, officer: Principal Executive Officer C/O WEBMD HEALTH CORP. 111 EIGHTH AVENUE NEW YORK NY 10011
Nomura Hiroshi director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Sumitomo Chemical Co., Ltd. 10 percent owner 7-1, NIHONBASHI 2-CHOME CHUO-KU TOKYO M0 103-6020
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd 10 percent owner 60 WALL STREET NEW YORK NY 10005
Gulfo Adele M. director ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957
Lo Andrew 10 percent owner C/O ALPHASIMPLEX GROUP, LLC ONE CAMBRIDGE CENTER, 9TH FLOOR CAMBRIDGE MA 02142
Viking Global Equities Master Ltd. 10 percent owner 55 RAILROAD AVENUE GREENWICH CT 06830
Sablich Kim officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Torti Frank director 2855 SAND HILL ROAD MENLO PARK CA 94025
Potter Myrtle S director 10 FINDERNE AVE BRIDGEWATER NJ 08807
Guinan Mark director C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094

Myovant Sciences Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)